NCT07354282已完成不适用
Retrospective, Multicenter, Real-world Observational Study of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma.
Spanish Oncology Genito-Urinary Group0 个研究点目标入组 200 人开始时间: 2025年5月13日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
The SOGUG-TIVOREAL study is a retrospective observational study with medications.
This study is based on the retrospective collection of data from patients who have been treated with Tivozanib as first-line therapy between 03/01/2019 and 08/31/2024 for metastatic renal cell carcinoma (mRCC).
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •- Patients ≥ 18 years old.
- •- Who have signed the informed consent form, except for patients who were deceased at the time of inclusion.
- •- Histological diagnosis of stage IV clear cell renal carcinoma.
- •- Who started treatment with Tivozanib as first-line therapy between March 1, 2019, and August 31,
- •- Who received treatment at the participating center.
排除标准
- •- Patients previously treated at another center who were later referred to one of the participating centers. In this case, the patient will be included in the center where the treatment was initiated.
- •- Explicit objection by the subject or their legal representative to participate in the study.
研究者
相似试验
已完成
不适用
A Study to Evaluate the Efficacy of a Facial Sunscreen in Adult Participants With Oily Skin and Signs of AgingNCT07310706Kenvue Brands LLC73
招募中
3 期
Vedolizumab Subcutaneous Long-term Open-label Extension Study in Pediatric Subjects2023-508804-39-00Takeda Development Center Americas Inc.32
招募中
3 期
A Long-term Study in Children and Teenagers with Ulcerative Colitis or Crohn’s Disease treated with Vedolizumab IV2023-509046-36-00Takeda Development Center Americas Inc.128
招募中
4 期
Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine NeoplasmsNCT07272512Shanghai Zhongshan Hospital350
进行中（未招募）
1 期
the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune DiseasesNCT07339540Tongji Hospital45